Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs 10X Genomics Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $107.92 (market cap $8.88B), while 10X Genomics Inc trades at $70.88 (market cap $9.53B). The key difference: Kymera Therapeutics Inc. Common Stock and 10X Genomics Inc are close in size by market cap, and 10X Genomics Inc is more actively traded (4,138,224 versus 1,028,790). Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and 10X Genomics Inc for 91 Days on average.
| KYMR | TXG | |
|---|---|---|
Market Cap | $8.88B | $9.53B |
Volume | 1,028,790 | 4,138,224 |
Sector | Health | Health |
52-Week High | $127.31 | $97.74 |
52-Week Low | $55.80 | $11.83 |
Typical Hold Time | 0 Days | 91 Days |
Enterprise Value | $8.27B | $9.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TXG trades at $71.79, down 4.52% on the day, amid a bearish technical signal. The company shows improving fundamentals with revenue of $642.82M in 2025 and a narrowing net loss of -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a patent victory, though insider selling and high valuation ratios like a P/S of 15.13 and EV/EBITDA of 241.6 present concerns.
The outlook is mixed; analyst consensus is a Buy with a $83.30 price target, but execution risks on Atera delivery and sustained profitability remain key. Upside depends on commercial success of new platforms, while downside risks include competitive pressures and failure to achieve positive earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
